Eli Lilly and Company announced detailed 52-week Phase 3 results from ACHIEVE-3, a head-to-head trial of its oral GLP-1 orforglipron versus oral semaglutide in adults with type 2 diabetes inadequately controlled on metformin. In the primary endpoint, orforglipron 36 mg reduced A1C by 2.2% from a baseline of 8.3% at week 52 versus a 1.4% reduction with oral semaglutide 14 mg. For a key secondary endpoint, participants receiving orforglipron 36 mg lost 19.7 lbs (9.2%) compared with 11.0 lbs (5.3%) on oral semaglutide 14 mg. The results were published in The Lancet and have already been presented as detailed results in the publication.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief on February 26, 2026, and is solely responsible for the information contained therein.
